OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Management of Myeloproliferative Neoplasms: A Focus on Polycythemia Vera and Myelofibrosis

home / peer-exchange / myeloproliferative-neoplasms-management
Overview of Myeloproliferative Neoplasms

EP. 1: Overview of Myeloproliferative Neoplasms

July 9th 2019
Differentiating Between Myeloproliferative Neoplasms

EP. 2: Differentiating Between Myeloproliferative Neoplasms

July 9th 2019
Diagnosing Polycythemia Vera

EP. 3: Diagnosing Polycythemia Vera

July 9th 2019
Suspecting Polycythemia Vera: Challenges in Diagnosis

EP. 4: Suspecting Polycythemia Vera: Challenges in Diagnosis

July 9th 2019
Frontline Therapy for Polycythemia Vera

EP. 5: Frontline Therapy for Polycythemia Vera

July 9th 2019
Treating Leukocytosis in Polycythemia Vera

EP. 6: Treating Leukocytosis in Polycythemia Vera

July 9th 2019
Cytoreductive Therapy in Polycythemia Vera

EP. 7: Cytoreductive Therapy in Polycythemia Vera

July 9th 2019
Ruxolitinib for Treatment of Polycythemia Vera

EP. 8: Ruxolitinib for Treatment of Polycythemia Vera

July 9th 2019
RESPONSE-2 Trial: Ruxolitinib for PV

EP. 9: RESPONSE-2 Trial: Ruxolitinib for PV

July 9th 2019
Interferon's Role in Treating Polycythemia Vera

EP. 10: Interferon's Role in Treating Polycythemia Vera

July 9th 2019
Diagnosis and Risk Stratification in Myelofibrosis

EP. 11: Diagnosis and Risk Stratification in Myelofibrosis

July 9th 2019
Ruxolitinib's Role in Treating Myelofibrosis

EP. 12: Ruxolitinib's Role in Treating Myelofibrosis

July 9th 2019
COMFORT Ruxolitinib Studies for Myelofibrosis

EP. 13: COMFORT Ruxolitinib Studies for Myelofibrosis

July 9th 2019
Dosing of Ruxolitinib in PV and MF

EP. 14: Dosing of Ruxolitinib in PV and MF

July 9th 2019
Fedratinib in MF: JAKARTA2 and FREEDOM Trials

EP. 15: Fedratinib in MF: JAKARTA2 and FREEDOM Trials

July 9th 2019
Emerging Agents Pacritinib and Momelotinib for MF

EP. 16: Emerging Agents Pacritinib and Momelotinib for MF

July 9th 2019
Other Pathways Studied for MF

EP. 17: Other Pathways Studied for MF

July 9th 2019
Unmet Needs and Future Directions in Treating MPNs

EP. 18: Unmet Needs and Future Directions in Treating MPNs

July 9th 2019

Latest Conference Coverage

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer

Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval

PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact